With the immediate and pressing need for sites to incorporate virtual elements, we talked with Anthony Costello at Medidata on what is being done in the industry to support the new way of performing clinical trials. Discussion centers around unified platforms and how these types of solutions can be beneficial for not only sites and patients, but the entire industry. There are several advantages of unifying services and tools at the site level and we discuss what some of those may look like. 

Clinical trials are moving towards trends of using more and more technology, even before COVID-19. This trend doesn't mean the role of the site has diminished, but just changed. What tools do sites need to help them succeed? How can flexible payment systems, direct-to-patient services, and telemedicine platforms enable site success?  Greenphire's Zach Hales discusses the different ways in which we need to start thinking to support patients where they are - in the clinic, the lab or in their home. Using technology to move research sites forward is critical to the growth of our industry. 

In an effort to ensure clinical trial continuity in the midst of COVID-19, more and more sponsors are moving towards Direct-to-Patient models to ensure patient access to medications. In order for sites to adequately prepare for this new approach, it is imperative to understand current trends and challenges as sponsors are approaching these models differently depending on their study and supply chain considerations.  

The Covid-19 pandemic caught everyone by surprise. Now that some time has passed and we are acclimating to the current climate, what should sites be thinking about when it comes to risk management and insurance?

This is not just an insurance discussion - it’s a discussion about risk. This includes the increased use of telemedicine and prevalence of decentralized clinical trials. This final interview with Hylant will help sites make important decisions regarding these matters

It pays to be prepared, especially in uncertain times. As sites struggle to maintain patient visits and keep trials moving forward amidst COVID-19, many are turning to remote monitoring and other elements of decentralized clinical trials (DCTs) to ensure their doors stay open. This SCRS Talks interview with Global Impact Partner (GIP) VirTrial provides insight into how sites can prepare to participate in DCTs or incorporate virtual visits into their trials. Listen in as VirTrial’s Director of Business Development, Emil Hoeck, discusses industry trends related to COVID-19, identifies best practices for going virtual to support your site’s sustainability, and addresses why now is the time to become virtual trial capable. 

The COVID-19 pandemic is a serious situation requiring careful navigation, and many companies associated with clinical trials are struggling to keep their doors open. How am I going to survive the next few months? What questions do I need to be asking? Who can I rely on for accurate information and guidance? Learn from Hylant as they sit down with SCRS to discuss how this is impacting sites, specifically their insurance policies.